Montreal’s Four Leading Pediatric Institutions Begin Largest Collaboration in Canadian History to Help Children with Musculoskeletal Disorders

    NEXT STORY
    Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
    PREV STORY
    Syneos Health Consulting Releases 11th Annual Survey of Biopharmaceutical Dealmakers
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1

    WOBURN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a ...

    author_avatar
    NASDAQ Market News

    Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD

    Achieved statistically significant and clinically meaningful additional improvement in peak lung function and faster ...

    author_avatar
    NASDAQ Market News

    Claus Frisenberg Pedersen, CCO i Oncology Venture köper aktier i bolaget

    Pressmeddelande Claus Frisenberg Pedersen, CCO i Oncology Venture köper aktier i bolaget Hørsholm, Denmark ...

    author_avatar
    NASDAQ Market News